Bayer to buy Vividion Therapeutics for $2bn ...Qatar

Gulf Times - News
Bayer to buy Vividion Therapeutics for $2bn
Bayer AG agreed to buy US biotech company Vividion Therapeutics Inc for as much as $2bn, snapping up a developer of promising therapies that only weeks ago filed for an initial public offering. The German drugmaker will pay $1.5bn up front and another $500mn in potential milestones for the San Diego-based biotech, it said in a statement on Thursday. The company also raised its profit forecast for the year.  For Bayer, the transaction is the latest in a string of deals intended to bolster innovation at the pharma unit and fuel growth as its top blockbuster medicines face the loss of patent protection. The company has worked to buoy its presence in cell and gene therapies, especially with the

Hence then, the article about bayer to buy vividion therapeutics for 2bn was published today ( ) and is available on Gulf Times ( Qatar ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bayer to buy Vividion Therapeutics for $2bn )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News